Oral Use Sarms steroid Powder Ligandrol Lgd-4033 for Muscle Gaining selina@ycgmp.com
Whatsapp:+8618872220826
Skype:selina@ycgmp.com
email:selina@ycgmp.com
Product Name: LGD-4033
Chemical Name: Ligandrol
CAS Number:1165910-22-4
EINECS Number: 212-729-3
Molecular Formula: C14H12F6N2O
Molecular Weight:338.25
Assay: 99.5%
Appearance:White powder
How LGD-4033 Works?
LGD-4033 works by tying androgen receptors selectively. It shows anabolic activity in the bones and muscles instead of harmfully affecting the prostate and sebaceous glands which usually happens when using steroids. LGD-4033 just concluded a study called Phase I Multiple Ascending Dose which included fit volunteers. This was an unplanned, double bind analysis stage that included a placebo. The objective was to form that using LGD-4033 was harmless and easy to stomach with a dose not beyond 22 mg a day.
Application:
LGD can be used for bulking, recomposition and cutting. It possesses the ability to add size while still reducing body fat, akin to primobolan. Another excellent characteristic it possesses is that it can be ran up to 12 weeks, whereas most orals can only be used for 4-6 week time periods. LGD produces steady gains throughout the entire 12 weeks, and it provides a user with an overall sense of well being where you feel excellent throughout the entire time of use. It has anabolic properties without the anabolic side effects.LGD-4033 also takes effect very quickly and will generally start to show results in the first week of use. In addition, it has shown to increase endurance, which will allow for more output during training, resulting in more gains being made. All these benefits make LGD ideal for any user because it provides an excellent kick-start and has an affinity to produce quality gains that show to be very clean but still substantial.
Dosage:
LGD-4033 should be dosed at 10 mg day, taken orally, once a day in the morning.LGD should be ran 8-12 weeks, with 12 weeks being ideal. A perfect combination for
fat loss is LGD-4033 with Andarine (S-4).
没有评论:
发表评论